<unk>  is currently FDA-approved to treat excessive daytime sleepiness associated with obstructive sleep apnea, narcolepsy, and shift work disorder. It is commonly used off-label to treat attention deficit hyperactivity disorder, chronic fatigue syndrome, and major depressive disorder, and has been repurposed as an adjunctive treatment for bipolar disorder. It has been shown to improve vigilance in air traffic controllers, however in the United States, sleep prevention medications such as Provigil (Modafinil) and Nuvigil<unk>  are not approved by the FAA for civilian controllers or pilots. Psychiatry Bipolar disorder<unk> , along with racemic modafinil, has been repurposed as an adjunctive treatment for acute depression in people with bipolar disorder. Meta-analytic evidence showed that add-on modafinil and<unk>  were more effective than placebo on response to treatment, clinical remission, and reduction in depressive symptoms, with only minor side effects, but the effect sizes are small and the quality of evidence has to be considered low, limiting the clinical relevance of current evidence. Schizophrenia In June 2010, it was revealed that a phase II study of<unk>  as an adjunctive therapy in adults with schizophrenia had failed to meet the primary endpoints, and the clinical program was subsequently terminated. However, a study published later that year showed that schizophrenic patients treated with<unk>  showed fewer of the negative symptoms of schizophrenia. Jet lag On March 30, 2010, the FDA declined to approve use of Nuvigil to treat jet lag.
Armodafinil
Adrafinil
Modafinil
Desmethylclozapine
Pirlindole
Influenzanet
Fluparoxan
Dexmethylphenidate